Profile
Paul Pyzowski is an entrepreneurial executive who thrives on the demanding yet rewarding challenges of technology commercialization and building innovative products, services, businesses and companies. After a decade of work in the electronic design automation, he turned his focus to applying semiconductor and electronics technologies to new areas and especially to life sciences markets in medical devices, drug discovery tools, and diagnostics.
As an executive he develops the strategy and tactics needed to commercialize new technologies, and as a business development professional he can make the game-changing deals and manage the strategic partnerships that transform a vision into reality. He can also pinch-hit in intellectual property and patent strategy, product development, marketing, and finance and operations.
Paul can quickly learn a new technology, understand its strategic implications, and convey this understanding to customers, technical and non-technical employees, academics, the media, and investors. He has lectured at MIT and at educational events sponsored by the IEEE and the Massachusetts Medical Development Group.
Much of Paul’s work has included applications of MEMS and semiconductor microfabrication technology in areas including DNA diagnostics, genomics, and neuromodulation-based medical devices. More recently he has also consulted in homeland security, factory automation, and alternative and clean energy.
Paul also brings unusual depth in international business dealings, having lived for nearly five years in Japan starting and operating a pan-Asian subsidiary for a public company, co-founding a Swiss medical device company, and earning an MBA in Europe. He is generally willing to fly just about anywhere outside of the US to advance his or his companies’ business.
Experience
Paul Pyzowski began his professional career at Ansoft Corporation, a Carnegie-Mellon spinout founded by one of his professors developing design tools for the electrical, electronics, and semiconductor industries. Paul joined the company as one of its earliest employees and over ten years became one of six executive officers, driving initiatives that directly led to growing the company from 8 people and negligible revenues to profitability at over US$30 million revenues, 240 people, and a NASDAQ listing. This included overseeing the launch of the company’s electronic design automation (EDA) products and a four-year stint in Japan setting up and managing a five-country, forty person pan-Asian subsidiary.
Paul subsequently turned his efforts to technology development and commercialization in the life sciences area. He was President of Network Biosystems, a privately held and financed MIT-Whitehead spinout where he moved the technology out of the lab, brought in over $10M in strategic and research financing, brought to market two initial products for DNA analysis, and refocused the company’s research efforts on rapid DNA analysis. He subsequently co-founded Aleva Neurotherapeutics, a Swiss-based medical device company developing advanced neurostimulation products for the treatment of movement disorders.
He obtained his BSEE from Carnegie-Mellon University, and an MBA from the Institute for Management Development in Switzerland.
